Stock Events

Stock Events

Atara Biotherapeutics 

€3.88
0
-€0.18-4.43% Today

Statistics

Day High
4.02
Day Low
3.84
52W High
8.8
52W Low
3.86
Volume
1,000
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
-0.28
-0.24
-0.2
-0.15
Expected EPS
-0.28125312017
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AT20.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap794.59M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, directly competing with Atara's allogeneic T-cell immunotherapy approach.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T and T-cell receptor (TCR) therapy space, similar to Atara's focus areas.
Novartis
NVS
Mkt Cap280.79B
Novartis is a major player in the CAR-T therapy market with Kymriah, competing in the same space as Atara's T-cell immunotherapy products.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has investments in CAR-T and other immunotherapies, positioning it as a competitor in the broader immunotherapy market.
AMGEN
AMGN
Mkt Cap185.74B
Amgen's focus on innovative therapies and investments in immuno-oncology position it as a competitor in the immunotherapy and cell therapy markets.

About

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Show more...
CEO
Dr. Pascal Touchon D.V.M.
Employees
173
Country
United States
ISIN
US0465132068

Listings

STU
DE
AT20.STU
MU
DE
AT20.MU
F
DE
AT20.F
XNAS
US
ATRA

0 Comments

Share your thoughts

FAQ

What is Atara Biotherapeutics stock price today?▼
The current price of AT20.STU is €3.88 EUR — it has decreased by -4.43% in the past 24 hours. Watch Atara Biotherapeutics stock price performance more closely on the chart.
What is Atara Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atara Biotherapeutics stocks are traded under the ticker AT20.STU.
Is Atara Biotherapeutics stock price growing?▼
AT20.STU stock has fallen by -8.06% compared to the previous week, the month change is a -55.9% fall, over the last year Atara Biotherapeutics has showed a -55.9% decrease.
When is the next Atara Biotherapeutics earnings date?▼
Atara Biotherapeutics is going to release the next earnings report on May 06, 2026.
What were Atara Biotherapeutics earnings last quarter?▼
AT20.STU earnings for the last quarter are -0.22 EUR per share, whereas the estimation was -0.15 EUR resulting in a -42.13% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Atara Biotherapeutics have?▼
As of April 29, 2026, the company has 173 employees.
In which sector is Atara Biotherapeutics located?▼
Atara Biotherapeutics operates in the Health & Wellness sector.
When did Atara Biotherapeutics complete a stock split?▼
Atara Biotherapeutics has not had any recent stock splits.
Where is Atara Biotherapeutics headquartered?▼
Atara Biotherapeutics is headquartered in Thousand Oaks, United States.